-
Signature
-
/s/ Brian Savage, Attorney-in-fact
-
Stock symbol
-
ABNB
-
Transactions as of
-
Aug 19, 2025
-
Transactions value $
-
-$709,487
-
Form type
-
4
-
Date filed
-
8/21/2025, 09:00 PM
Reporting Owners (1)
Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
Blecharczyk Nathan |
Chief Strategy Officer, Director, 10%+ Owner |
888 BRANNAN STREET, SAN FRANCISCO |
/s/ Brian Savage, Attorney-in-fact |
2025-08-21 |
0001834147 |
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
ABNB |
Class A Common Stock |
Tax liability |
-$428K |
-3.41K |
-1.81% |
$125.49 |
185K |
Aug 19, 2025 |
Direct |
|
transaction |
ABNB |
Class A Common Stock |
Conversion of derivative security |
|
+400 |
+4.04% |
|
10.3K |
Aug 19, 2025 |
By Trust |
F1 |
transaction |
ABNB |
Class A Common Stock |
Sale |
-$281K |
-2.25K |
-1.22% |
$125.20 |
183K |
Aug 20, 2025 |
Direct |
F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
ABNB |
Class B Common Stock |
Conversion of derivative security |
$0 |
-400 |
0% |
$0.00 |
45.4M |
Aug 19, 2025 |
Class A Common Stock |
400 |
|
By Trust |
F1 |
holding |
ABNB |
Class B Common Stock |
|
|
|
|
|
11.3M |
Aug 19, 2025 |
Class A Common Stock |
11.3M |
|
By 2020 GRAT II |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: